Перегляд за Автор "Bardhan, Mainak"

Зараз показуємо 1 - 2 з 2
  • Ескіз недоступний
    Документ
    Immunological and inflammatory effects of infectious diseases in circadian rhythm disruption and future therapeutic directions
    (Springer, 2023-01-19) Huang, Helen; Mehta, Aashna; Jacob, Kalmanovich; Anand, Ayush; Bejarano, Maria Chilo; Garg, Tulika; Khan, Nida; Тonpouwo, Gauvain Kankeu; Shkodina, Anastasiia D.; Bardhan, Mainak; Шкодіна, Анастасія Дмитрівна
    Background Circadian rhythm is characterised by daily variations in biological activity to align with the light and dark cycle. These diurnal variations, in turn, influence physiological functions such as blood pressure, temperature, and sleep–wake cycle. Though it is well established that the circadian pathway is linked to pro-inflammatory responses and circulating immune cells, its association with infectious diseases is widely unknown. Objective This comprehensive review aims to describe the association between circadian rhythm and host immune response to various kinds of infection. Methods We conducted a literature search in databases Pubmed/Medline and Science direct. Our paper includes a comprehensive analysis of findings from articles in English which was related to our hypothesis. Findings Molecular clocks determine circadian rhythm disruption in response to infection, influencing the host’s response toward infection. Moreover, there is a complex interplay with intrinsic oscillators of pathogens and the influence of specific infectious processes on the CLOCK: BMAL1 pathway. Such mechanisms vary for bacterial and viral infections, both well studied in the literature. However, less is known about the association of parasitic infections and fungal pathogens with circadian rhythm modulation. Conclusion It is shown that bidirectional relationships exist between circadian rhythm disruption and infectious process, which contains interplay between the host’s and pathogens’ circadian oscillator, immune response, and the influence of specific infectious. Further studies exploring the modulations of circadian rhythm and immunity can offer novel explanations of different susceptibilities to infection and can lead to therapeutic avenues in circadian immune modulation of infectious diseases.
  • Ескіз недоступний
    Документ
    Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression
    (Springer, 2022-06) Boiko, D. I.; Shkodina, A. D.; Hasan, Mohammad Mehedi; Bardhan, Mainak; Kazmi, Syeda Kanza; Chopra, Hitesh; Bhutra, Prerna; Baig, Atif Amin; Skrypnikov, A. M.; Бойко, Дмитро Іванович; Шкодіна, Анастасія Дмитрівна; Скрипніков, Андрій Миколайович
    A complex pathogenesis involving several physiological systems is theorized to underline the development of depressive disorders. Depression is accompanied by circadian regulation disruption and interaction with the functioning of both central and peripheral oscillators. Many aspects of melatonin function unite these systems. The use of drugs for circadian rhythm disorders could inspire a potential treatment strategy for depression. Melatonin plays an essential role in the regulation of circadian rhythms. It exerts effect by activating two types of melatonin receptors, type 1A (MT1) and 1B (MT2). These are G-protein-coupled receptors, predominantly located in the central nervous system. MT1/MT2 agonists could be a useful treatment approach according to all three prevalent theories of the pathogenesis of depression involving either monoamines, synaptic remodeling, or immune/inflammatory events. MT1/MT2 receptors can be a potential target for novel antidepressants with impact on concentrations of neurotrophins or neurotransmitters, and reducing levels of pro-inflammatory cytokines. There is an interesting cross-talk mediated via the physical association of melatonin and serotonin receptors into functional heteromers. The antidepressive and neurogenetic effects of MT1/MT2 agonists can also be caused by the inhibition of the acid sphingomyelinase, leading to reduced ceramide, or increasing monoamine oxidase A levels in the hippocampus. Compounds targeting MT1 and MT2 receptors could have potential for new anti-depressants that may improve the quality of therapeutic interventions in treating depression and relieving symptoms. In particular, a combined effect on MT1 and/or MT2 receptors and neurotransmitter systems may be useful, since the normalization of the circadian rhythm through the melatonergic system will probably contribute to improved treatment. In this review, we discuss melatonergic receptors as a potential additional target for novel drugs for depression.